GlucaGen Glucagon Injection Recalled for Temperature Control Deviations
GlucaGen (glucagon) injection vials are being recalled due to temperature abuse during manufacturing that may have compromised product stability. The 187 vials were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a critical emergency injection medication due to temperature-control deviations during manufacturing. While no reported illnesses are stated in the source, temperature abuse of glucagon—used for severe hypoglycemia—presents a risk-of-harm where drug efficacy in emergency situations may be compromised.
Plain-English summary
GlucaGen (glucagon) for injection, 1 mg per vial, is a prescription medication in a single-dose kit form. The product (NDC 0597-0260-10) is manufactured for Boehringer Mannheim and distributed by McKesson Medical-Surgical Inc. A total of 187 vials have been recalled and were distributed nationwide throughout the United States.
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations discovered during manufacturing. Specifically, the product experienced temperature abuse, which may have affected the product's stability and integrity.
McKesson Medical-Surgical is unable to identify the specific lot number for each recipient. Customers should refer to the recall notification letters they received, which include the distribution dates and shipping information for their affected product.
Patients and healthcare providers who have received this product should contact McKesson Medical-Surgical Inc. or their local pharmacy for return and replacement instructions.
The recalled product
- Product
- GlucaGen (glucagon) for injection, 1 mg per vial, single dose kit, Rx only, Manufactured for: Boehringer Mannheim, NDC 0597-0260-10
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Hazard
- temperature-abuse
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27